Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.
Valuation and Earnings
This table compares Nurix Therapeutics and DiaMedica Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $36.77 million | 76.70 | -$264.46 million | ($3.45) | -7.88 |
| DiaMedica Therapeutics | N/A | N/A | -$32.77 million | ($0.72) | -9.22 |
Volatility & Risk
Nurix Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Nurix Therapeutics and DiaMedica Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
| DiaMedica Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Nurix Therapeutics presently has a consensus price target of $34.21, indicating a potential upside of 25.92%. DiaMedica Therapeutics has a consensus price target of $12.00, indicating a potential upside of 80.72%. Given DiaMedica Therapeutics’ higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Nurix Therapeutics.
Insider & Institutional Ownership
10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Nurix Therapeutics and DiaMedica Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
| DiaMedica Therapeutics | N/A | -77.76% | -69.43% |
Summary
Nurix Therapeutics beats DiaMedica Therapeutics on 8 of the 13 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
